A pediatric neurologic assessment score may drive the eculizumab-based treatment of Escherichia coli-related hemolytic uremic syndrome with neurological involvement.

Paolo GiordanoGiuseppe Stefano NettiLuisa SantangeloGiuseppe CastellanoVincenza CarboneDiletta Domenica TorresMarida MartinoMichela SestaFranca Di CuonzoMaria Chiara RestaAlberto GaetaLeonardo MilellaMaria ChironnaCinzia GerminarioGaia ScaviaLoreto GesualdoMario Giordano

Published in: Pediatric nephrology (Berlin, Germany) (2018)

A "neurological score" may be a useful tool to drive the early treatment of CNS complications in STEC-HUS with eculizumab, although future perspective controlled studies are urgently needed to validate this therapeutic approach.

Keyphrases

escherichia coli
risk factors
young adults
combination therapy
staphylococcus aureus
cystic fibrosis
candida albicans